GSK plc (GSK)
After hours:
| Previous close | 43.50 |
| Open | 43.50 |
| Bid | 0.00 x 2200 |
| Ask | 0.00 x 800 |
| Day's range | 43.17 - 43.64 |
| 52-week range | 33.33 - 43.84 |
| Volume | |
| Avg. volume | 3,380,630 |
| Market cap | 88.649B |
| Beta (5Y monthly) | 0.27 |
| PE ratio (TTM) | 15.92 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 1.50 (3.46%) |
| Ex-dividend date | 16 May 2024 |
| 1y target est | N/A |
- GlobeNewswire
BioVersys Announces Expansion of Strategic Collaboration With GSK and Extension of Its Series C Round by CHF 12.3 Million
Strategic collaboration with GSK expanded to accelerate clinical development of alpibectir for the treatment of tuberculosisGSK to participate in Series C Extension with equity investmentSeries C financing round extended overall by CHF 12.3 million to CHF 44.9 million BASEL, Switzerland, May 07, 2024 (GLOBE NEWSWIRE) -- BioVersys AG, a multi-asset, clinical stage biopharmaceutical company focusing on research and development of novel antibacterial products for serious life-threatening infections
- Business Wire
Positive RUBY phase III data show potential for Jemperli (dostarlimab-gxly) combinations in more patients with primary advanced or recurrent endometrial cancer
PHILADELPHIA, March 16, 2024--RUBY phase III data show potential for Jemperli (dostarlimab-gxly) combinations in more patients with primary advanced or recurrent endometrial cancer
- Business Wire
GSK Doubles COiMMUNITY Grant Funding, Launches Patient Resources, as Adult Vaccination Rates Begin to Show Promising Rise
PHILADELPHIA, March 07, 2024--GSK doubles COiMMUNITY grant funding, launches patient resources, as adult vaccination rates begin to show promising rise
